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Introduction
α-N-acetylgalactosaminidase (nagalase) is known to accumulate 
in the serum of cancer patients, where it mediates the deglycosyl-
ation of group-specific component (GC), best known as vitamin 
D-binding protein (VDBP), which is the precursor of GC protein-
derived macrophage-activating factor (GcMAF). Deglycosylated 
VDBP cannot be converted into GcMAF1 and decreased GcMAF 
levels reportedly promote immunodeficiency in individuals 
bearing advanced neoplasms.2 The increase in nagalase activity 
observed in cancer patients is mostly due to the fact that malig-
nant cells release enzymatically active nagalase.3 Thus, serum 
nagalase activity reflects not only tumor burden and aggressive-
ness, but also the clinical progression of the disease.4–7 Nowadays, 
the assessment of serum nagalase activity is proposed as a reliable 
means to determine the clinical severity of multiple neoplasms.3
In serum, nagalase acts as an endo- (but not as an exo-) 
enzyme, being unable to deglycosylate an N-acetylgalactosamine 
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(GalNAc) residue of GcMAF.5 Thus, circulating nagalase can-
not degrade exogenous GcMAF.5–7 This observation suggested 
that patients with elevated nagalase activity may benefit from 
the exogenous provision of GcMAF. Alongside, GcMAF was 
observed to exert multiple anticancer effects in vivo and in vitro, 
both in experimental and in spontaneous tumor models. Given 
the impact of GcMAF on macrophages and their central role 
anticancer immune responses, GcMAF is widely considered as 
an immunotherapeutic agent.7
However, in addition to stimulating tumor-infiltrating mac-
rophages,8 GcMAF not only directly inhibits the proliferation 
of various human cancer cells in vitro,9,10 but also reverts the 
malignant phenotype of human breast cancer cells.10 Moreover, 
GcMAF reportedly inhibits angiogenesis, thus depriving neo-
plastic lesions of the oxygen and nutrient supplies that are needed 
for tumor progression and metastasis.10–13 Recently, it has been 
proposed that the antineoplastic effects of GcMAF are mediated 
by the vitamin D receptor (VDR), and it was demonstrated that 
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here.16 Thus, while some studies present large and impressive sta-
tistics obtained from large clinical cohorts, others may report a 
limited number of noteworthy cases, as we do here. According to 
this novel, authoritative, epistemological approach, “all of these 
stories become evidence of what works in medicine.”16 Therefore, 
we believe that the clinical cases reported below point to benefi-
cial effects for the administration of GcMAF to advanced can-
cer patients, prompting further studies to formally address this 
possibility.
Results
The mean pre-GcMAF treatment serum nagalase activity doc-
umented in our patient cohort was 2.84 ± 0.26 nM/min/mg, 
with a range of 1.00–5.60 nM/min/mg (Table 1). At the time of 
second testing (average interval = 112 d), the mean serum nag-
alase activity in the course of GcMAF treatment was 2.01 ± 0.22 
nM/min/mg, with a range of 1.00–3.20 nM/min/mg. The differ-
ence between these values was statistically significant (p < 0.05). 
Of note, no patient of this cohort was initially observed to be 
within the laboratory reference range for serum nagalase activ-
ity (0.90–0.92 nM/min/mg). At the time of final testing (aver-
age interval = 263 d), the mean serum nagalase activity of the 
patient cohort was 1.59 ± 0.17 nM/min/mg, with a range of 
GcMAF stimulates an intracellular signaling pathway impinging 
on cyclic AMP. This signal transduction cascade could actually 
be responsible for death of malignant cells exposed to GcMAF.12 
Taken together, these in vitro and in vivo findings lend a ratio-
nale to the observation that GcMAF exert dramatic anticancer 
effects in (at least a fraction of) patients with advanced cancer.5–7 
Of note, in the aforementioned studies, the anticancer effects of 
GcMAF were evaluated by measuring serum nagalase activity as 
a marker of tumor burden and progression.2,3,14
The biological effects of GcMAF have been documented in 
a variety of experimental systems and make the subject of more 
than 50 peer-reviewed papers published during the past 20 y.15 
Because of the solid scientific rationale underlying the compas-
sionate use of GcMAF in advanced cancer patients, hundreds of 
physicians in all parts of the world have adopted this approach for 
a variety of indications in which it could prove useful. Here, we 
present a series of clinical cases exemplifying the results that have 
been obtained with the administration of GcMAF to patients 
with diverse types of advanced cancers, with a particular focus 
on the effects of GcMAF on serum nagalase activity. We are well 
aware that these cases, because of their heterogeneity and reduced 
number, can be considered anecdotal. However, a very recent 
study on the evaluation of clinical practice strongly encourages 
the re-evaluation of individual cases such as those presented 
Table 1. nagalase levels before and after gcMAF therapy*
N° Gender Age Tumor type
Serum nagalase activity
Pre draw 
date
Pre 
result
First-post 
draw date
First-post 
result
Days 
between 
pre and 
first post 
draw
Last draw 
date
Last 
result
Days 
between 
pre and 
last draw
Pre-last 
difference
1) M 64 Bladder cA
October, 
2012
2.90
January, 
2013
2.60 92 −0.30
2) M 63 Bladder cA July, 2011 3.10
February, 
2012
2.30 215
October, 
2012
1.40 458 −1.70
3) F 69 Bladder cA May, 2011 4.10
October, 
2011
2.30 153
December, 
2012
0.75 580 −3.35
4) F 60 Ovarian cA June, 2012 3.30 June, 2012 3.20 7
november, 
2012
2.80 153 −0.50
5) F 62 Ovarian cA
August, 
2012
2.70 - - -
February, 
2013
2.00 184 −0.70
6) F 61 Ovarian cA
December, 
2012
2.60 - - -
February, 
2013
2.20 62 −0.40
7) M 67 Prostate cA
August, 
2012
3.40 - - -
December, 
2012
2.80 122 −0.60
8) M 76 Prostate cA April, 2011 2.00
August, 
2011
1.20 122
December, 
2012
0.75 610 −1.25
9) M 65 Prostate cA
October, 
2011
1.90
February, 
2012
1.70 123
October, 
2012
1.20 366 −0.70
10) F 66 Breast cA
August, 
2011
1.70
January, 
2012
1.00 153
December, 
2012
0.60 487 −1.10
*serum nagalase activity values are presented as nM/min/mg. The last column (pre-last nagalase difference) illustrated the decrease in serum nagalase 
activity between the initiation of gc protein-derived macrophage-activating factor (gcMAF) therapy (pre) and the last time point of testing (last). For 
patients who had serum nagalase activity tested in more than two instances, the results of the additional determination (first-post) are reported in the 
column “First-post results.” *p < 0.05; **p < 0.01. cA, carcinoma.
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Table 1. nagalase levels before and after gcMAF therapy*
N° Gender Age Tumor type
Serum nagalase activity
Pre draw 
date
Pre 
result
First-post 
draw date
First-post 
result
Days 
between 
pre and 
first post 
draw
Last draw 
date
Last 
result
Days 
between 
pre and 
last draw
Pre-last 
difference
11) F 63 Breast cA May, 2011 5.60
October, 
2011
2.90 153
October, 
2012
1.10 519 −4.50
12) M 63
Tongue 
squamous 
cell cA
July, 2012 3.00
september, 
2012
1.50 62
December, 
2012
1.00 153 −2.00
13) F 55
Tongue 
squamous 
cell cA
november, 
2012
1.20 - - -
February, 
2013
0.87 92 −0.33
14) M 54
colorectal 
cA
July, 2012 3.90 - - -
October, 
2012
2.00 92 −1.90
15) F 58
head/neck 
squamous 
cell cA
June, 2012 2.90 July, 2012 2.70 30
February, 
2013
2.00 245 −0.90
16) M 72 Larynx cA May, 2011 4.70
October, 
2011
2.00 153
December, 
2012
0.90 580 −3.80
17) F 35
squamous 
cell cA
June, 2012 1.50
september, 
2012
1.10 92 −0.40
18) F 69
Follicular 
lymphoma
June, 2012 1.00
August, 
2012
1.30 61
January, 
2013
1.20 214 0.20
19) F 66 Lymphoma
August, 
2012
2.20 - - -
november, 
2012
1.90 92 −0.30
20) M 42
grade III 
anaplastic 
oligoden-
droglioma
november, 
2012
3.00 - - -
January, 
2013
2.60 61 −0.40
Max - - - - 5.60 - 3.20 215 - 2.80 610 -
Min - - - - 1.00 - 1.00 7 - 0.60 61 -
Mean - - - - 2.84 - 2.01* 112 - 1.59** 263 -
SEM - - - - 0.26 - 0.22 19.17 - 0.17 44.90 -
*serum nagalase activity values are presented as nM/min/mg. The last column (pre-last nagalase difference) illustrated the decrease in serum nagalase 
activity between the initiation of gc protein-derived macrophage-activating factor (gcMAF) therapy (pre) and the last time point of testing (last). For 
patients who had serum nagalase activity tested in more than two instances, the results of the additional determination (first-post) are reported in the 
column “First-post results.” *p < 0.05; **p < 0.01. cA, carcinoma.
0.60–2.80 nM/min/mg. The difference between this value and 
the serum nagalase activity recorded before the initiation of 
GcMAF treatment was also statistically significant (p < 0.01).
Narrative description of some notable clinical cases from 
The Netherlands. The following reports were collected and 
communicated by Dr Steven Hofman (CMC, Capelle aan den 
Ijssel; The Netherlands) and refer to the years 2011–2012. In 
addition to GcMAF, most patients were prescribed supplementa-
tion of vitamins D and A. Additional supplements are indicated 
when assumed. Most of the patients did not assume conventional 
anticancer chemotherapy along with GcMAF. However, several 
patients had been subjected to conventional anticancer therapies 
in the previous years, as indicated in individual reports. When 
patients assumed conventional therapeutics, such as hormones, 
in the course of GcMAF administration (e.g., patient #8), 
this is indicated in the individual report. When not indicated 
otherwise, patients received 100 ng GcMAF weekly, as a single 
intramuscular injection, in line the commonly accepted recom-
mendations.5–7 Original reports are in italics. Each case is referred 
to with progressive numbers, as in Table 1.
In Figure 1, the decrease of serum nagalase activity in the patient 
cohort is plotted in function of the consecutive testing. Of note, 
since this is a retrospective analysis and not a clinical trial, nagalase 
determinations were not performed at the same time point in each 
individual patient. The overall shape of the graph, however, is very 
similar if not completely superimposable to that of other graphs of 
the same type that have previously been reported.5–7,17
2. Male, born 1950. Carcinoma of the urine-bladder since 2009, 
previously treated with chemo-solutions locally. Nagalase level at pre-
sentation on July 4, 2011: 3.10. February 10, 2012: 2.30. May 25, 
2012: 1.80. October 26, 2012: 1.40. Treatment with GcMAF and 
acupuncture, later GcMAF only (later intravenous route). Bladder 
(continued)
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GcMAF treatment, and persisted until the last available determi-
nation, i.e., about 19 mo thereafter. The difference in serum nag-
alase activity as recorded before at last determination and before 
the initiation of GcMAF therapy was −3.35 nM/min/mg. The 
last available value of serum nagalase activity, 0.75 nM/min/mg, 
was within the normal range.
8. Male, born 1937. Prostate carcinoma found by PSA in 2009, 
no specific complaints. Treated by hormone-injections, which gave 
complaints. Before and in the same year colon carcinoma was found, 
and operated after irradiation and chemotherapy (no untreated 
tumor/metastases probable). Nagalase level at presentation on 
April 6, 2011: 2.00. August 29, 2011: 1.20. January 5, 2012: 0.81. 
July 5, 2012: 0.67. December 6, 2012: 0.75. Treatment with acu-
puncture and GcMAF; after some time, the hormone treatment was 
discontinued and complaints, also non-specific, improved a lot. Stays 
on low-frequency surveillance. Again, serum nagalase activity 
returned to normal values (0.75 nM/min/mg) after about 20 mo 
of GcMAF treatment. A decrease in nagalase activity, however, 
was evident already at the first test, i.e., 4 mo after the initiation 
of GcMAF treatment. According to the literature,7 the normal-
ization of serum nagalase levels in prostate cancer patients may 
represent an index of tumor eradication.
9. Male, born 1948. Prostate carcinoma in 2008; prostate 
extirpated in 2009 with good prognosis. However aspecific reportts 
fatigue and pain stayed. GcMAF treatment was started, together 
with a few acupuncture treatments. Nagalase level at presentation 
on October 21, 2011: 1.90. February 2, 2012: 1.70. October 19, 
2012: 1.20. Complaints decreased gradually and the injections were 
performed intravenously later on. The treatment continues.
10. Female, born 1947. Carcinoma of left breast (found on sur-
vey), operated with sentinel nodes in 2010, chemotherapy 4 of 6 
series, no specific complaints left. Still some malaise, fatigue and 
sleep-disorder. Nagalase level at presentation on August 9, 2011: 
1.70. January 16, 2012: 1.00. March 12, 2012: 0.72. December 11, 
2012: 0.60. GcMAF-treatment (predominantly intravenous route) 
combined with acupuncture. GcMAF discontinued in April 
2012. Aspecific complaints diminished. Patient still seen every few 
months. A significant decrease in serum nagalase activity could 
be observed after 5 mo of GcMAF treatment. Such a decrease 
persisted even after the interruption of GcMAF, and serum nag-
alase activity was normalized about 16 mo after the initiation of 
therapy. According to the literature,5 the normalization of serum 
nagalase activity in breast carcinoma patients may represent an 
index of tumor eradication.
11. Female, born 1950. Carcinoma of left breast, specific com-
plaints, metastases probable. After local operation, irradiation of 
thorax, combined with chemotherapy, Herceptin-therapy. Partly 
complaints in association with treatments. Nagalase level at presen-
tation on May 11, 2011: 5.60. October 6, 2011: 2.90. February 21, 
2012: 1.80. October 18, 2012: 1.10. Treated with intramuscular, 
later intravenous GcMAF, and a few acupuncture-treatments. No 
further complaints (subsided in 3–6 weeks), still in intravenous 
GcMAF regimen. A significant decrease in serum nagalase activ-
ity could be observed approximately 5 mo after the initiation of 
therapy. Approximately after 17 mo of GcMAF treatment, serum 
nagalase levels approached normal values.
considered clean by urologist in summer 2012. GcMAF-treatment 
continued. In this case, the consistent decrease in serum nagalase 
activity was associated with a significant clinical improvement. 
The drop in nagalase activity was evident at the first post-treat-
ment testing, about 7 mo after the initiation of GcMAF treat-
ment, and persisted until the last available determination, i.e., 
about 15 mo thereafter. The difference in serum nagalase activity 
as recorded before at last determination and before the initiation 
of GcMAF therapy was −1.70 nM/min/mg.
3. Female, born 1944. Bladder carcinoma treated since 2011 by 
urologist with curettage and BCG. Nagalase level at presentation on 
May 9, 2011: 4.10. October 24, 2011: 2.30. April 3, 2012: 1.40. 
September 10, 2012: 1.00. December 4, 2012: 0.75. During the 
nagalase testing period the Patient was advised to inject intramuscu-
lar GcMAF weekly, but the Patient was not consistent. The bladder 
was considered in good condition on several occasions this period by 
the treating urologist. Also in this case, a consistent decrease in 
serum nagalase activity was associated with a significant clinical 
improvement. Such a decrease in nagalase activity was evident at 
the first post-treatment testing, about 5 mo after the initiation of 
Figure 1. Time course of gcMAF treatment in 7 cancer patients with 
serum nagalase activity as a prognostic index. Data correspond to the 
patients described in the section “narrative description of some notable 
clinical cases from The netherlands.” serum nagalase activity determi-
nations were not performed at the same time point in each individual 
patient, as detailed in Table 1. Patients are indicated with consecutive 
numbers as in the results section and Table 1.
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improvement was associated with a significant decrease in serum 
nagalase activity, which approached the normal range in approxi-
mately 5 mo. To the best of our knowledge, this is the first case 
of a patient affected by squamous cell carcinoma of the tongue 
receiving GcMAF. Also patient n. Thirteen (Table 1) was treated 
with GcMAF for a squamous cell carcinoma of the tongue and 
showed a decrease in serum nagalase activity in about 3 mo.
14. Male, age 54. Colorectal cancer. Nagalase level at first testing 
in July 2012: 3.90. In October 2012: 2.00. Discontinued. In this 
case, a significant decrease of serum nagalase activity could be 
documented approximately 3 mo after the initiation of GcMAF 
therapy. We are not aware of the reasons that led to treatment 
discontinuation.
15. Female, age 58. Squamous cell carcinoma of the head and 
neck. Nagalase level at first testing in June 2012: 2.90. In July 2012: 
2.70. In February 2013: 2.00. Improved. In this case, a minimal 
decrease in serum nagalase activity as observed after 1 mo of 
GcMAF administration was associated with clinical benefits.
17. Female, age 35. Squamous cell carcinoma. Nagalase level 
at first testing in June 2012: 1.50. In September 2012: 1.10. 
Discontinued. In this case, a decrease of serum nagalase activity 
was observed after 3 mo of GcMAF therapy. We are not aware of 
the reasons that led to treatment discontinuation.
18. Female, age 69. Follicular lymphoma. Nagalase level at first 
testing in June 2012: 1.00. In August 2012: 1.30. In January 2013: 
1.20. Improved. In this case, no association between serum nag-
alase activity, GcMAF treatment and clinical conditions could 
be revealed.
19. Female, age 66. Lymphoma. Nagalase level at first testing in 
August 2012: 2.20. In November 2012: 1.90. Improved. In this 
case, a clinical improvement was associated with a significant 
decrease in serum nagalase activity in about 3 mo after the initia-
tion of GcMAF treatment.
Discussion
GcMAF has been shown to inhibit multiple aspects of neoplas-
tic transformation in vitro, in a variety of tumor models.5–10 The 
clinical cases reported here are heterogeneous and refer to patients 
with different types of neoplasms and at different stages of malig-
nant progression. These cases include cancer patients in whom 
the effects of GcMAF had not been described before, such as sub-
jects bearing various types of head and neck carcinoma (including 
tumors of the larynx and tongue), lymphoma, oligodendrocy-
toma and ovarian carcinoma. In some instances, patients were 
simultaneously affected by multiple types of tumors, as reported 
in the narrative description. In many cases, patients received 
GcMAF along with other complementary treatments, such as 
acupuncture or administration of nutritional supplements. In 
all cases, GcMAF therapy was initiated at late stages of tumor 
progression, as conventional therapies were obviously preferred at 
less advanced stages. Thus, most of the cases described here fall 
under the category of compassionate treatment. In fact, most of 
these patients had undergone conventional anticancer therapy in 
the previous years and had referred to GcMAF treatment when 
conventional chemo- or radiotherapy had proven ineffective or 
16. Male, born 1941. Larynx-carcinoma found and treated with 
curettage and irradiation in 2010. Hemorrhagic-recto-colitis in 
anamnesis, few complaints after 2005. Bladder carcinoma found 
in 2011, treated by local curettage and several cycles of BCG-
instillations. Complaints related to tumor growth and treatments, 
no chemotherapy. Treatment consisted of acupuncture and GcMAF 
intramuscular, and later intravenous injections on a weekly basis. 
Nagalase level at presentation on May 16, 2011: 4.70. October 
4, 2011: 2.00. February 10, 2012: 1.20. June 15, 2012: 1.00. 
October 23, 2012: 0.88. December 20, 2012: 0.90. During the 
immunotherapy with GcMAF there were interesting developments. 
Insisting on bladder extirpation by the urologists, coped with one 
change of urologist, two second opinions by a specialized cancer clinic 
and later by an urologist of the operation team scheduled. From the 
Patients side there were several favorable adjustments in lifestyle, like 
discontinuation of smoking and adopting a daily intake of cod-liver-
oil and salvia-leaf (his own initiative). In the face of the urologists 
opinion I decided to give the GcMAF twice weekly over a period of 
six weeks. The last opinion of the treating urologist was to postpone a 
more final decision to February, due to a much better impression of 
the bladder mucosa beginning in January 2013. There is optimism 
in the three named actors in the current situation. In this case, a 
significant decrease of in serum nagalase activation following the 
administration of GcMAF was associated with significant clini-
cal benefits, consistent with previous reports.7
Narrative description of some notable clinical cases from the 
United States of America. The following reports were communi-
cated by RE and refer to the years 2012–2013. In most patients, 
the weekly administration of 100 ng GcMAF i.m. was initiated 
in August 2012, and the first assessment of serum nagalase activ-
ity was performed immediately before the initiation of treatment. 
None of the patients assumed conventional anticancer chemother-
apy during along with GcMAF. Here, we report only those cases 
for which as least two nagalase determinations were available.
1. Male, age 64. Bladder carcinoma. Nagalase level at first test-
ing in October 2012: 2.90. In January 2013: 2.60. Improved. In 
this case, a decrease in serum nagalase activity could be docu-
mented in about 3 mo of GcMAF treatment and was associated 
with clinical improvement.
4. Female, age 60. Ovarian carcinoma. Nagalase level at first 
testing in June 2012: 3.30. November 2012: 2.80. CA-125 tumor 
marker in December 2012: 15.7. In February 2013: 19.1 Improved. 
The weekly administration of GcMAF resulted in a significant 
decrease of serum nagalase activity in about 3 mo. Such a decrease 
was associated with clinical benefits. These changes, however, 
were not (as yet) associated with a decrease in the circulating lev-
els of cancer antigen 125 (CA-125), another tumor marker.
7. Male, age 67. Prostate carcinoma. Nagalase level at first testing 
in August 2012: 3.40. In December 2012: 2.80. Improved. In this 
case, clinical benefits were associated with a significant decrease 
in serum nagalase activity in about 4 mo from the initiation of 
GcMAF therapy. These results are consistent with the findings 
reported above as well as with previously described cases.7
12. Male, age 63. Squamous cell carcinoma of the tongue. 
Nagalase level at first testing in July 2012: 3.00. In September 
2012: 1.50. In December 2012: 1.00. Improved. Again, clinical 
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assessments performed in the course of GcMAF therapy, and - 
together with the assessment of serum nagalase activity testing 
and VDR polymorphisms - it may assist physicians in monitor-
ing the response of individual patient to GcMAF and adjust-
ing doses and schedules in the course of treatment, if required. 
Studies investigating the impact of GC polymorphisms on the 
response of cancer patients to GcMAF therapy as well as the 
contribution of distinct GC variants to the relative amounts of 
“non-inducible,” inactive GcMAF species20 will also be instru-
mental in determining the most correct approach to GcMAF 
administration.
The results reported here are consistent with previous results5–7 
as well as with a recent publication by Inui et al.,21 who described 
three clinical cases successfully treated with combinatorial thera-
peutic regimens including subcutaneous or intramuscular injec-
tions of GcMAF-containing human serum. At variance with this 
latter study, the results presented here were obtained with highly 
purified GcMAF, ruling out the effects of other serum proteins 
that might have acted as confounding factors.
In conclusion, the clinical cases presented here reinforce the 
hypothesis that GcMAF could become part of anticancer immu-
notherapeutic regimens.
Materials and Methods
GcMAF production. Physicians obtained GcMAF from Immuno 
Biotech Ltd (Guernsey, UK). GcMAF was highly purified 
according to previously described procedures.7 Briefly, VDBP was 
isolated from purified human serum obtained from the American 
Red Cross, using either 25-hydroxyvitamin D3-sepharose high 
affinity chromatography or actin-agarose affinity chromatogra-
phy. Bound material was eluted and further processed by incuba-
tion with three immobilized enzymes. The resulting GcMAF was 
filter sterilized. Protein content and concentration of the GcMAF 
solution were assayed using standard Bradford protein assay 
methods.22 At the end of the production process, GcMAF was 
checked for sterility in-house as well as externally, by independent 
laboratories. The safety and biological activity of GcMAF were 
tested on human monocytes,13 human breast cancer cells,10 and 
chick embryo chorionallantoic membranes.12
Data collection. A retrospective chart review for the analy-
sis of nagalase testing was accomplished on the initial cohort 
of patients seen by the clinicians (RE and Dr Steven Hofman, 
CMC, Capelle aan den Ijssel; The Netherlands). All records were 
reviewed by physicians for confirmation of serum nagalase activ-
ity values, diagnoses, time intervals between testing, GcMAF 
dosing and clinical responses. The diagnosis of cancer was con-
firmed by other treating physicians.
GcMAF administration. The administration of GcMAF to 
individual patients was performed exclusively by their physicians 
(RE and Dr Steven Hofman, CMC, Capelle aan den Ijssel; The 
Netherlands), according to the national rules and regulations. 
Original clinical records are conserved by the physicians, in their 
respective locations, as indicated. In the Results section, clini-
cal cases are reported as close as possible to the originals notes 
of physicians, with minimal grammar and spelling corrections. 
intolerable, as described in the individual reports. Since this is an 
open-label, non-controlled, retrospective analysis, caution must 
be employed in drawing a cause-effect relationship between treat-
ment and clinical outcome. However, the response to GcMAF 
was often relatively robust and certain trends stand out.
Trends from Dutch cases. (1) All patients presented with 
serum nagalase activity well above the normal value, that is about 
0.95 nM/min/mg. (2) All patients showed a significant decrease 
in serum nagalase activity following GcMAF injections. (3) 
In all cases, serum nagalase activity was reduced at the second 
assessment, and such a decrease persisted in the following deter-
minations. (4) In 4/7 cases, serum nagalase activity returned to 
normal levels by the last assessment.
Trends from American cases. (1) All patients, but one, pre-
sented with serum nagalase activity well above the normal value. 
Patient #18, indeed, presented with a serum nagalase activity 
that was very close to normal. (2) In most patients, a signifi-
cant decrease in serum nagalase activity was observed upon the 
administration of GcMAF. In patient #18, such a decrease was 
not associated with clinical benefits, even though her serum nag-
alase activity was always on the low side. This lack of a strict 
inverse relationship between serum nagalase activity and clini-
cal responses has been recently observed in a study describing 
the effects of GcMAF in autistic children. Most of these patients 
showed indeed a decrease in serum nagalase activity as well as a 
significant improvement of symptoms, but the two phenomena 
were not strictly correlated with each other.18
A significant point that emerges from the analysis of the cases 
described above is the apparent absence of GcMAF-related side 
effects. This point, which has previously been documented in 
autistic children,18 is of great importance when GcMAF is consid-
ered for the compassionate treatment of patients with advanced 
or incurable diseases. As a matter of fact, in many countries, the 
complete absence of side effects is a prerequisite for the com-
passionate administration of substances that have not yet been 
approved by local sanitary authorities.
Obviously, these preliminary observations require a pro-
longed follow-up period to determine the best indications for the 
compassionate administration of GcMAF. As of today, GcMAF 
has been used (always as a compassionate therapy) with encour-
aging results in patients affected by virtually all types of cancers 
and at all stages of disease progression. However, it is tempting 
to hypothesize that patients bearing specific types and/or stages 
of malignancy might obtain consistent clinical benefits from 
the administration of GcMAF. Also the genetic background of 
patients, in particular in terms of VDR polymorphisms, might 
influence the individual response to GcMAF. In fact, we have 
recently demonstrated that the degree of response of human 
monocytes to GcMAF is associated with individual VDR geno-
types.13 It can therefore be hypothesized that the antineoplastic 
effects of GcMAF may also be influenced by such polymor-
phisms. Moreover, it should be kept in mind that the prognosis of 
patients affected by all types of cancers is dependent upon their 
nutritional and inflammatory status, which can be monitored 
by the Prognostic Inflammatory and Nutritional Index (PINI).19 
The PINI score might therefore become part of the laboratory 
www.landesbioscience.com OncoImmunology e25769-7
Statistical methods. Statistical comparisons between the 
serum nagalase activity observed before and after (at two distinct 
time points) the administration of GcMAF were performed by 
Student’s t-tests.
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Since each physicians used described the condition of individual 
patients in a different fashion, some heterogeneity in these notes 
has to be expected. The notes are purposely presented as they had 
been written so that each reader can draw her/his conclusions.
Serum nagalase activity determinations. Serum nagalase 
testing was performed at ELN Laboratories (Bunnik, The 
Netherlands) following the procedure published by Yamamoto 
et al.14 In particular, serum nagalase activity was determined by 
using an endpoint enzymatic assay based on a chromogenic sub-
strate. ELN Laboratories established a reference range of 0.32–
0.95 nM/min/mg of substrate based on serum samples collected 
from healthy volunteers, a range slightly higher than that previ-
ously reported, which was of 0.35–0.65 nM/min/mg.14 Further 
studies on elevated numbers of subjects will establish the most 
appropriate reference range. Irrespective of this issue, since all 
determinations were performed in the same laboratory, a relative 
decrease of in serum nagalase activity following GcMAF admin-
istration was used as an index of therapeutic efficacy.
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